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FEDERAL FUNDING OF HUMAN EMBRYO STEM CELL
RESEARCH: ADVOCATING A BROADER APPROACH
JASON R. BRASWELL*
INTRODUCTION
On August 9, 2001, in an historic evening television address to
the nation, President George W. Bush announced a change in the
long standing United States policy denying federal funding for human
embryonic stem cell ("ES cell") research: federal funding would be
made available for research on certain existing human ES cell lines.1
In his address, President Bush told the American public that prelimi-
nary, privately-funded research has led many scientists to believe that
further ES cell research "offers great promise that could help improve
the lives of those who suffer from many terrible diseases-from
juvenile diabetes to Alzheimer's, from Parkinson's to spinal cord
injuries."2  He also warned, however, that "[e]mbryonic stem cell
research is at the leading edge of a series of moral hazards" and that
"while we must devote enormous energy to conquering disease, it is
equally important that we pay attention to the moral concerns raised
by the new frontier of human embryo stem cell research. Even the
most noble ends do not justify any means. '3
These excerpts from President Bush's address frame the basic is-
sues that must be faced when determining whether federal funds
should be directed to human ES cell research. On one hand, ES cells
have a seemingly enormous, though as of yet unproven, potential for
use in developing medical treatments for some of mankind's most
abhorred ailments. On the other hand, to create human ES cell lines,
scientists must remove cells from a human embryo that is rendered
* B.S., Biology with Honors in Biology Research, University of Alabama at Birmingham,
2000; J.D. Candidate, Chicago-Kent College of Law, 2003. Thanks to Professor Lori Andrews,
Alison Scheidler, and everyone at the Institute for Science, Law, and Technology for their
invaluable insight, assistance, and contributions.
1. President George W. Bush, Remarks by the President on Stem Cell Research (Aug. 9,




nonviable by the process. This creates a prickly moral issue that
raises concerns as to the correct characterization of an embryo and
the overall value of human life, both for embryos and human beings
afflicted with ailments that may prove susceptible to ES cell-derived
treatments.
Federal funding is crucial to the success of human ES cell re-
search. It serves both a pragmatic and symbolic function.4 Pragmati-
cally, it provides researchers with the necessary funding to continue
and expand their work. Symbolically, it places a "stamp of approval"
on the researchers' work and eases the transition of the technology
into the mainstream. If human ES cell research is going to succeed in
the United States, it needs federal funding.
This Note critiques President Bush's policy of federally funding
ES cell research and concludes that too much of human ES cells'
potential cannot be realized under the Bush plan. While the Bush
plan is an improvement over a complete denial of federal funding for
human ES cell research, its limiting of funding to research on a
relatively small number of approved ES cell lines poses a significant
obstacle to ES cell science. A more liberal plan of federal funding is
needed, one that would fund not only research on existing stem cell
lines, but also creation of and research on new ES cell lines.
A more liberal funding plan would give scientists the ability to
transcend limitations that are inherent in existing stem cell lines, such
as the lines' questionable viability' and unsuitability for use in devel-
oping transplantation products. It would also lead to a more diverse
pool of ES cell lines that would allow researchers to work around
existing intellectual property rights and to develop therapeutic
products that could benefit the largest possible portion of the popula-
tion. A more liberal funding plan would also benefit taxpayers
because they would receive more effective and efficient research for
their tax dollars.
Part I of this Note explains what an ES cell is, examines the po-
tential uses of ES cells, and briefly outlines the ethical and moral
issues surrounding ES cells. It also explores the importance of federal
funding to ES cell research and outlines the Bush plan of federally
funding human ES cell research as well as two alternative plans. Part
II examines exactly how the Bush funding policy constrains ES cell
4. See infra Part I.D.
5. See Michael Lasalandra, Government Scientists: 60 Stem Cell Lines Enough, BOSTON
HERALD, Aug. 11, 2001, at 8, available at 2001 WL 3808463.
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science and medical research, focusing on four major concerns that
illustrate the need for broader federal funding of human ES cell
research. Finally, this Note concludes that a broader approach to
federally funding human ES cell research is necessary if ES cell
science is going to reach its full potential.
I. BACKGROUND
A. What Are Human Embryonic Stem Cells?6
Every living thing is made of cells. 7 The cell is one of the most
fundamental units of life. Complex organisms such as humans are
made up of millions of cells.' In these complex organisms, the cells
are organized into tissues, the tissues are organized into organs, the
organs are organized into organ systems, and the organ systems are
organized into the organism. 9
Over two hundred types of cells make up the human body.10
These cells vary from blood cells to muscle cells to nerve cells." But
as different as these cells are, they all have the same ultimate origin:
the totipotent 2 cells of the human embryo.13 These totipotent cells
have the ability to form any type of cell present in the human body.
Additionally, each totipotent cell is capable of developing into a
complete embryo."4 In the course of normal embryological develop-
ment, these totipotent cells give rise to genetically identical copies of
themselves that, in turn, become the specialized cell types of the body
6. This Note can, of course, only skim the surface of the science behind ES cells. For a
good review of the state of science of stem cell research, see DEP'T OF HEALTH AND HUMAN
SERVS., STEM CELLS: SCIENTIFIC PROGRESS AND FUTURE RESEARCH DIRECTIONS (2001), at
http://www.nih.gov/news/stemcell/fullrptstem.pdf.
7. ROBERT A. WALLACE, BIOLOGY 57 (7th ed. 1997).
8. The best current estimates are that the average human body is comprised
of about 100 trillion cells. The Wellcome Trust, A Genomics Primer,
http://www.wellcome.ac.uk/en/genome/thgpri.htm.
9. WALLACE, supra note 7, at 334-35.
10. BRUCE ALBERTS ET AL., MOLECULAR BIOLOGY OF THE CELL 36 (3d ed. 1994).
11. See id. at 36-37.
12. "Totipotent" is defined as "capable of developing into a complete embryo or organ[.]"
WEBSTER'S NEW WORLD COLLEGE DICTIONARY 1512 (4th ed. 1999).
13. See ALBERTS, supra note 10, at 32 (stating that "[t]he cells of almost every multicellular
organism are generated by repeated division from a single precursor cell.").
14. DEP'T OF HEALTH AND HUMAN SERVS., supra note 6, at F-10.
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by switching particular genes on or off.15 The process by which cells
go from stem cells to specialized cells is known as differentiation.
16
ES cells are derived from these same totipotent cells of the early
human embryo.1 7 Up to the eight-cell stage of development, each cell
of a mammalian embryo is totipotent.18 The totipotent cells used to
create ES cells are typically extracted from the inner cell mass of a
day-five (postfertilization) human embryo known as a blastocyst,
usually comprised of between two hundred and two hundred fifty
cells.,9 This extraction process renders the embryo nonviable.
Rather than being totipotent, ES cells are pluripotent: they can
give rise to differentiated cell types from the ectoderm, the endo-
derm, and the mesoderm, the three primary germ layers of the
embryo.20 During embryological development, the various cells of the
human body arise from these three primary germ layers through
further differentiation.2' This means that an ES cell can differentiate
into almost all of the cells of the body.22 Human ES cells and human
embryonic germ cells 23 ("EG cells") are the only known sources of
pluripotent human stem cells,24 leading many scientists to conclude
that pluripotent ES cells offer greater promise than alternative stem
15. ALBERTS, supra note 10, at 34-35.
16. Id. at G-8 (defining differentiation as the "[p]rocess by which a cell undergoes a change
to an overtly specialized cell type").
17. James A. Thomson et al., Embryonic Stem Cell Lines Derived from Human Blastocysts,
282 Sci. 1145, 1145 (1998).
18. ALBERTS, supra note 10, at 1058.
19. DEP'T OF HEALTH AND HUMAN SERVS., supra note 6, at 13. These embryos can be
fresh or frozen. Id. at C-1. Human embryos at the day-five blastocyst stage are also the
embryos commonly used for implantation by in vitro fertilization ("IVF") clinics because this
stage of development parallels the stage at which a human embryo would implant into the wall
of the uterus in vivo. Id. at 13. This makes excess products of IVF an attractive source of
embryos to be used in ES cell creation.
20. DEP'T OF HEALTH AND HUMAN SERVS., supra note 6, at 5.
21. WALLACE, supra note 7, at 311.
22. DEP'T OF HEALTH AND HUMAN SERVS., supra note 6, at 5.
23. Human EG cells are derived from the primordial germ cells of developing fetuses and
embryos. DEP'T OF HEALTH AND HUMAN SERVS., supra note 6, at ES-2. Other types of stem
cells, such as adult stem cells or umbilical stem cells, are able to differentiate into some other
types of cells, but are not pluripotent. Id. at ES-6. EG cells and ES cells are similar in many
respects, but differ in their origins and growth characteristics. Id. at 14. EG cells are isolated
from primordial germ cells extracted from the gonadal ridge (the precursor to the testes or
ovaries) of a five- to ten-week fetus. Id. at ES-2. Also, EG cells have been maintained for only
seventy to eighty population doublings in vitro, whereas ES cells have been maintained for
several hundred population doublings. Id. at 14. In addition, EG cells show different differen-
tiation characteristics than ES cells show. Id. at 14-15. Policies of federally funding human EG
cell research is beyond the scope of this Note.
24. Id. at ES-1.
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cell technologies such as adult stem cells or hematopoietic 2 stem
cells.
2 6
In addition to being pluripotent, ES cells are also capable of
unlimited undifferentiated proliferation in vitro.27  That is, ES cells,
when cultured in the laboratory, will divide infinitely and will remain
stem cells, as opposed to differentiating into specialized cell types.
Human ES cells have been propagated in vitro for approximately two
years and several hundred population doublings.28 This characteristic
makes it possible to use one ES cell to create an ES cell line. A cell
line is an unlimited source of cells of a standardized, genetically
homogenous type. 29 In other words, once you have one ES cell, you
theoretically have an infinite supply of that ES cell that can be used
for research, medical, or other purposes. These ES cell lines provide
the human ES cells that researchers use for their work.
B. The Promise of Stem Cells
The intense interest in human ES cells comes from their poten-
tial medical uses. Because human ES cells are pluripotent, they can
theoretically be manipulated into any human cell or even into any
human tissue.30 ES cells are viewed, therefore, as a potential source
of replacement cells and tissues that could be used to repair damage
caused by disease or injury.3' For example, Israeli scientists recently
announced that they had succeeded in transforming human ES cells
into immature heart-tissue cells in their lab.32 It has been estimated
that three thousand Americans die every day from diseases that may
25. Some hematopoietic stem cells derive from umbilical cord blood and are sometimes
referred to as umbilical stem cells. See id. at 46-47.
26. Stem cell technologies other than ES cells are beyond the scope of this Note. However,
most researchers are keen to see both embryonic and adult stem cells pursued. As Art
Caplan, a bioethicist at the University of Pennsylvania in Philadelphia, points out,
placing bets on embryonic over adult stem cells, or vice versa, is like standing in the
18th century and trying to predict the future of aviation from watching a balloon and a
kite. It is far too early in stem-cell technology to say which approach will ultimately fly.
Masters of Disguise, THE ECONOMIST, Mar. 16, 2002, at 80-81, available at 2002 WL 7245517.
27. Thomson, supra note 17, at 1145.
28. DEP'T OF HEALTH AND HUMAN SERVS., supra note 6, at 14. Other types of stem cells,
such as adult stem cells or umbilical stem cells, are able to differentiate into some other types of
cells, i.e., they are multipotent, but are not pluripotent. Id. at ES-6.
29. ALBERTS, supra note 10, at 892-93.
30. DEP'T OF HEALTH AND HUMAN SERVS., supra note 6, at ES-1.
31. Id.
32. Bill Hoffmann, Doctors Turn Stem Cells to Heart Tissue, N.Y. POST, Aug. 2, 2001, at 19.
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be treatable in the future with therapies derived from ES cell re-
search. 33
There are also potential medical uses of human ES cells that do
not involve transplantation. For example, human ES cells have been
proposed as a way to study early events of human development. 34
Another proposed use of human ES cells is to test candidate thera-
peutic drugs and screen toxins. 35 Human ES cells also have potential
use in developing new methods for genetic engineering. 36 Perhaps the
medical potential of ES cells was best summed up when former NIH
director Harold Varmus, testifying on stem cell technology before
Congress, stated: "There is almost no realm of medicine that might
not be touched by this innovation.
'37
C. The Catch: Ethical and Moral Issues Regarding Human ES Cells
Along with the incredible medical potential of human ES cells,
however, comes a catch: serious ethical and moral concerns over
human ES cells that arise from ES cells' origins. Current techniques
for deriving human ES cells require extraction of cells from a human
embryo, which leaves the embryo nonviable.3 8 This fact has lead to
widespread and outspoken opposition to research using human ES
cells from, among others, prolife groups and the Catholic Church. 31
Their argument against ES cell research is analogous to their argu-
ment against abortion: life begins at conception, so the destruction of
an embryo in the process of creating human ES cells is equivalent to
killing any other human being.40
Opposite these ES cell opponents, the chief proponents of ES
cell research41 have been patients' groups representing individuals
inflicted with the maladies for which ES cell technology seems to hold
the most promise. The most notable ES cell proponents are Nancy
33. Robert P. Lanza et al., The Ethical Reasons for Stem Cell Research, 292 SCI. 1299
(2001).
34. DEP'T OF HEALTH AND HUMAN SERVS., supra note 6, at 17.
35. Id. at 17-18.
36. Id. at 18.
37. Anne McLaren, Stem Cells: Golden Opportunities with Ethical Baggage, 288 SCI. 1778
(2000).
38. See, e.g., Thomson, supra note 17, at 1145 (1998).
39. See Alexander Morgan Capron, Stem Cells: Ethics, Law and Politics, 20
BIOTECHNOLOGY L. REP. 678, 687 (2001); Gretchen Vogel, Bush Squeezes Between the Lines
on Stem Cells, 293 SCI. 1242 (2001).
40. Capron, supra note 39, at 687.
41. This ignores, of course, the scientific community with its vested interest.
[Vol 78:423
FEDERAL FUNDING OFHUMANSTEM CELL RESEARCH
Reagan42, lobbying on behalf of Alzheimer's disease patients such as
President Ronald Reagan; Christopher Reeve43, lobbying on behalf of
victims of spinal cord injuries; Mary Tyler Moore"4, lobbying on
behalf of diabetes patients; and Michael J. Fox45, lobbying on behalf
of Parkinson's disease patients.
46
These groups' argument for human ES cell research is as follows:
the sacrifice of an unwanted human embryo is justifiable if done for
the benefit of those human beings suffering from maladies treatable
by ES cell-derived techniques. 47  This argument is echoed by some
legislators who insist that supporting the destruction of human
embryos for the purpose of developing lifesaving medical treatments
is, in effect, a "prolife" position. 8
Opponents of ES cell research counter with the fact that ES cells'
medical promise is currently unproven. 49 This argument leaves ES
cell researchers in a catch-22: researchers cannot get funding because
ES cells' medical promise is unproven, and researchers cannot prove
ES cells' promise because they cannot get funding. This catch-22 is
unacceptable for something that has as much theoretical medical
promise as ES cells.
Another point that proponents of ES cell research emphasize is
that the embryos used to create ES cell lines are typically surplus
embryos that were created by in vitro fertilization for reproductive
purposes and are no longer needed.5" Because these embryos, if not
implanted, will simply be destroyed," many question the harm in
42. Capron, supra note 39, at 681.




46. Support from luminaries such as these have turned stem cell research into "Holly-
wood's latest social cause." Id.
47. See Richard 0. Hynes, Prepared Testimony of Richard 0. Hynes, Ph.D., President of
the American Society for Cell Biology Before the Senate Appropriations Committee Labor,
Health & Human Services Subcommittee Research, Federal News Service, Sept. 14, 2000,
available at 2000 WL 23832686.
48. Capron, supra note 39, at 681. Professor Capron also notes that this argument seems to
resonate with much of the public.
49. See Brad Evenson, Research Miracles Just Hype for Now, NAT'L POST, Aug. 10, 2001, at
A13, available at 2001 WL 25980519 ("The hope that stem cells could one day cure disease is so
speculative that private companies have deemed it too risky [for investment].").
50. Hynes, supra note 47.
51. Each year thousands of embryos are destroyed at their progenitors' requests. Lanza,
supra note 33, at 1299.
2003]
CHICAGO-KENT LAW REVIEW
using them to benefit others.52 The recent advent of embryo adop-
tions, however, has removed some of the poignancy from this point.
Groups, such as Nightlight Children Adoptions' Snowflake program
in Fullerton, California, are springing up that link infertile couples to
couples that have excess embryos from IVF treatments." The excess
embryos are implanted in the donee mother and, in successful cases,
the result is pregnancy and a child. While the number of excess
embryos is currently far greater than the demand for embryo adop-
tions, some have predicted that the current ES cell controversy will
lead to a bridging of that gap.
54
President Bush summarized the ethical and moral concerns sur-
rounding ES cell research well when he broke them down into two
questions: "First, are these frozen human embryos human life, and
therefore, something precious to be protected? And second, if
they're going to be destroyed anyway, shouldn't they be used ... for
research that has the potential to save and improve other lives?" 55
D. The Importance of Federal Funding to Human ES Cell Research
There are currently no limits on private funding of human ES
cell research. Scientists working with private funding are free to
conduct whatever research they want on whatever ES cell lines they
want.5 6 So why is the question of federal funding for human ES cell
research such a pressing concern? There are two answers to this
question. Government funding is critical to ES cell research both
pragmatically, because it provides necessary resources, and symboli-
cally, because it places the significant weight of the government
behind the research. 7 Federal funding of ES cell research also gives
52. See, e.g., Hynes, supra note 47. This approach is complicated, however, by the issue of
embryo adoptions, which is addressed infra. See Jennifer Bayot, New Faces in Stem Cell Debate:
Foes of Research Cite Embryonic Adoptions, BOSTON GLOBE, July 18, 2001, at Al, available at
2001 WL 3942817.
53, Bayot, supra note 52, at Al.
54. Id.
55. President George W. Bush, supra note 1.
56. See Vogel, supra note 39. A few states do have laws that act as barriers to stem cell
research, but these are largely inconsequential.
57. See ANDREA L. BONNICKSEN, IN VITRO FERTILIZATION: BUILDING POLICY FROM
LABORATORIES TO LEGISLATURES 100 (1989) ("Affirmative policy eases techniques symboli-
cally, by placing the weight of the government behind them, or pragmatically, by allocating
resources for their use.").
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the government more control over the ES cell researchers and the
direction of ES cell research. 8
Pragmatically, federal funding is perceived as crucial to almost all
basic research. In fact, federal funding accounts for about 85 percent
of sponsored research expenditures in the United States. s9 ES cell
research is currently being stifled by a lack of funding.60 Although
private funding for human ES cell research should be increasingly
forthcoming as ES cell science comes closer to reaching its potential,
at this early stage of ES cell research, federal funding is imperative
for significant progress.
61
Symbolically, federal funding seems to reflect some sort of gov-
ernment, and therefore public, stamp of approval on funded re-
search. 62  By providing federal funding for human ES cell research,
the government confers legitimacy on ES cell science and eases its
transition into the mainstream.
63
The government also increases its control over ES cell science
when it provides federal funding.64 ES cell research grant proposals
seeking federal funds must face a government review panel which
functions as an independent review by specialized experts; an ES cell
researcher using only private funds, however, needs only satisfy a
review by an in-house review board whose review is often cursory.65
This gives the government the opportunity to make sure that only
efficient and effective research is being conducted. If the reviews are
properly conducted, taxpayers benefit by getting more research bang
58. See id. at 107.
59. ASS'N OF UNIV. TECH. MANAGERS, AUTM LICENSING SURVEY: FY 1999, SURVEY
SUMMARY 1 (2000), at http://www.autm.net/surveys/99/survey99A.pdf.
60. See Evenson, supra note 49.
61. But see Capron, supra note 39, at 697.
Jim Clark, founder of several Silicon Valley companies, has decided to withhold $60
million of the $150 million he had pledged to Stanford University for a center for
biomedical engineering and science because he has concluded that the politicization of
stem cell research in the United States means that the "new future for medicine and
biology and for resulting entrepreneurship" that he had intended to stimulate at Stan-
ford will instead occur abroad, especially in the U.K.
Id. For a parallel problem, see the discussion of the flight of scientists in Part I.B.
62. See BONNICKSEN, supra note 57, at 100-16. Professor Bonnicksen addresses federal
funding and legislation of IVF in its early days. The position of IVF at that stage is analogous to
the position that ES cell science is in right now.
63. Id. at 101.
64. "[Flederal funding [is] a double-edged sword for the researcher. It brings in dollars to
support research but also opens the project to regulation and control." Id. at 107.
65. Id.
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for their tax buck, and ES cell science benefits by being steered
towards the most effective and efficient avenues.
Federal funding is crucial to ES cell science's success. It provides
necessary pragmatic and symbolic support for the research and
subjects ES cell science to a degree of government control, which, if
properly exercised, will benefit ES cell science.
E. The Bush Plan to Federally Fund Human ES Cell Research and
Alternative Plans
President Bush's plan, currently followed by the NIH in distrib-
uting research dollars, allows federal funding of research on human
ES cell lines that existed prior to his August 9, 2001 announcement,
but withholds federal funding from research on any human ES cell
lines derived after this date.66 To be eligible for federal funding, the
human ES cell lines must also have been derived from embryos that
were created for fertility treatments but are no longer needed, and
the embryos must have come from couples that gave their informed
consent free of any financial inducements. 67 The NIH initially re-
leased a list of sixty-four human ES cell lines ("approved ES cell
lines") that meet these criteria. 6 The number of approved ES cell
lines has, however, subsequently increased to seventy-eight and may
be subject to even further upward revision.69 Research on any other
human ES cell lines is not eligible for federal funding under Bush's
plan.
President Bush's plan marks a departure from long standing
United States policy that acted as a de facto ban on federal funding of
human ES cell research. 0 ES cell research opponents would like to
66. Vogel, supra note 39, at 1242.
67. Id. at 1243.
68. NATIONAL INSTITUTES OF HEALTH (NIH), UPDATE ON EXISTING HUMAN
EMBRYONIC STEM CELLS (Aug. 27, 2001), at http://www.nih.gov/news/stemcellI082701list.htm.
69. NIH Human Embryonic Stem Cell Registry, http://escr.nih.gov.
70. In 1993, shortly after entering office, President Clinton ordered the repeal of a
moratorium, issued during the presidency of George H. W. Bush, on federal funding of certain
fetal tissue research. Federal Funding of Fetal Tissue Transplantation Research, 58 Fed. Reg.
7457 (Jan. 22, 1993). Congress added legislative force to the repeal of the moratorium with the
passage of the NIH Revitalization Act of 1993, which also created statutory guidelines
governing fetal tissue transplantation. Pub. L. No. 103-43, Title I(A), 107 Stat. 122, 126-33
(codified at 42 U.S.C. §§ 289g, 289g-1, 289g-2). While up until this point federal funding for
human ES cell research would have been relatively uninhibited, Congress followed the NIH
Revitalization Act of 1993 with the 1996 enactment of the "Dickey Amendment," a rider to an
appropriations bill, that unambiguously prohibited research resulting in the destruction of
embryos. The Balanced Budget Downpayment Act, I, Pub. L. No. 104-99, § 128, 110 Stat. 26
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see a reversion to this state once again. At least one congressman,
Representative Ron Lewis (R-KY), has indicated that he might
introduce a bill that would unambiguously ban federal funding of
human ES cell research." It seems unlikely that any such bill would
ever become law, however, because it appears that a sizable majority
of Congress supports at least some federal funding for human ES cell
research.
72
This Note advocates enacting a plan for federally funding human
ES cell research that is broader than the Bush plan. What is particu-
larly needed is funding of research on stem cell lines created after the
cutoff date set by the Bush plan. One bill that set forth such a plan
was the New Century Health Advantage Act.73 This bill would have
removed all statutory limitations on federal funding of human ES cell
research. 74 Although this bill is now moot due to the expiration of the
legislation it sought to repeal (the Dickey Amendment75), it is a useful
example because of the very broad funding approach that it proposes.
II. THE SHORTCOMINGS OF THE BUSH PLAN
The Bush plan will allow researchers to conduct much of the ba-
sic ES cell research that is needed, but it will not allow the researchers
to reach their end goal, revolutionary medical applications of this
technology. While there is something to be said for President Bush's
(1996). The Dickey Amendment has been reenacted annually. See Consolidated Appropria-
tions-FY 2001, Pub. L. No. 106-554, §510, 114 Stat. 2763 (2000). It should be noted that
President Clinton, later in the second term of his presidency, supported a Department of Health
and Human Services ("HHS") interpretation of the Dickey Amendment that would have
allowed funding for research on human ES cells as long as the ES cells were obtained from
private sources; however, this approach to federally funding human ES cell research was never
utilized. See Jason H. Casell, Note, Lengthening the Stem: Allowing Federally Funded
Researchers to Derive Human Pluripotent Stem Cells from Embryos, 34 U. MICH. J.L. REFORM
547, 566-67 (2001); Judy Holland, Scientists Fear Loss of Stem Cell Funds, MILWAUKEE J.
SENTINEL, Jan. 15, 2001, at Al, available at 2001 WL 9333428. Therefore, the practical effect on
federal funding of human ES cell research was an absolute ban. For an overview of federal
funding of fetal research in the pre-Clinton years, see Capron, supra note 39, at 682-83.
71. Sheryl Henderson Blunt, Embryos Split Prolifers, CHRISTIANITY TODAY, Sept. 3, 2001,
available at 2001 WL 10317801.
72. See, e.g., id.; see also Lee Davidson, Bennet Supports Stem-Cell Research, DESERT
NEWS, July 21, 2001, at Al, available at 2001 WL 24492908.
73. H.R. 2838, 107th Cong. (2001). The Stem Cell Research Act of 2001, currently in both
the House of Representatives and the Senate, advocates a similar position but sets some
restrictions upon embryos that can be used and prohibits funding of research resulting in human
cloning or the creation of human embryos. H.R. 2059, 107th Cong. (2001); S. 723, 107th Cong.
(2001).
74. H.R. 2838, 107th Cong. (2001).
75. See supra note 70.
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political "splitting the baby,"76 his plan is not an acceptable long-term
solution. This Section sets forth four specific shortcomings of the
Bush plan, and shows how a broader plan of funding would remedy
these shortcomings.
A. Property Rights
One shortcoming of the Bush plan is that by limiting research
funding to seventy-eight existing human ES cell lines," it artificially
constrains the market for these cell lines, and, consequently, inflates
the value of property rights in these cell lines. This is due simply to
the law of supply and demand.78 A broader plan of federal funding,
one that allows funding for later derived ES cell lines as well, would
broaden the pool of ES cell lines available to researchers and, there-
fore, would decrease the value of property rights in ES cells.
1. The Obstacles that Property Rights Create
The problems that property rights in the approved ES cell lines
will create for researchers are already becoming clear. Officials from
BresaGen, an Australia-based biotechnology company that has four
human ES cell lines that qualify for federal funding under President
Bush's plan, recently announced that they will make BresaGen's ES
cell lines available to academic researchers at no charge. 9 These ES
cell lines, however, will be far from free. Allan Robbins, BresaGen's
senior vice president and chief scientific officer, has explained that
the ES cell lines will be made available to the researchers for "no
upfront payment in exchange for some first right of refusal for any
intellectual property that researchers invent." 8 Similarly, the Wis-
consin Alumni Research Foundation ("WARF"), a company formed
to patent research discoveries at the University of Wisconsin, Madi-
son, has agreed to make its ES cell lines available to NIH researchers
and researchers at nonprofit institutions that receive NIH grants for a
76. See, e.g., Vogel, supra note 39.
77. These seventy-eight lines are owned by just fourteen organizations. G6teborg
University in Sweden holds the largest number of approved lines with nineteen. NIH Human
Embryonic Stem Cell Registry, http://escr.nih.gov.
78. See RICHARD A. POSNER, ECONOMIC ANALYSIS OF LAW 9 (3d ed. 1986).
79. Tim Friend, Free Stem-Cell Lines Will Be Offered to Researchers, USA TODAY, August
22, 2001, at D10.
80. Id.
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nominal fee to cover handling and distribution expenses. However,
WARF will retain all commercial rights to the materials.,"
The most valuable property rights that the fourteen owners of
approved ES cell lines have are the intellectual property rights in the
cell lines. It is these intellectual property rights that will most hinder
ES cell science.
Illustrative of the problems caused by intellectual property rights
in the approved human ES cell lines is a patent owned by WARF,
U.S. Patent No. 6,200,806 ( "'806 patent").82 The inventor of WARF's
'806 patent is Dr. James A. Thomson, a University of Wisconsin
researcher who was the first individual to isolate human ES cells.
83
WARF's '806 patent claims human ES cells with various enumerated
characteristics, two methods for isolating human ES cells, and a cell
line developed using one of the claimed methods8 4 WARF clearly
has full property rights, both personal and intellectual, in five human
ES cell lines that it developed that meet requirements for federal
funding under President Bush's plan. Based upon the eleven claims
of the '806 patent, however, WARF is claiming intellectual property
rights in every human ES cell line that qualifies for federal funding
under President Bush's plan."5 And there may well be merit to that
claim.
6
WARF's broad claims of intellectual property rights in the hu-
man ES cell lines has led would-be major players in ES cell science to
scramble to negotiate with WARE. WiCell Research Institute, Inc., a
company formed by WARF to handle its ES cell lines, and the Public
Health Service ("PHS") of the United States Department of Health
and Human Services recently signed a Memorandum of Understand-
ing ("MOU") for research use of WiCell's (WARF's) existing patent
rights and five human ES cell lines that are eligible for federal re-
search funding under President Bush's plan.
87
81. News Release, National Institutes of Health, National Institutes of Health and WiCell
Research Institute, Inc., Sign Stem Cell Agreement (Sept. 5, 2001), at
http://www.nih.gov/news/pr/sep200l/od-05.htm [hereinafter NIH].
82. (issued Mar. 13, 2001); see also U.S. Patent No. 5,843,780 (issued Dec. 1, 1998).
83. See Thomson, supra note 17.
84. U.S. Patent No. 6,200,806 (issued Mar. 13, 2001); see also U.S. Patent No. 5,843,780
(issued Dec. 1, 1998).
85. See Friend, supra note 79.
86. See Michael D. Lemonick, Keeper of the Stem Cells: Now That There's Federal Money
for Research, Can Patent Holders Meet Demand for the Precious Lines?, TIME, Aug. 27, 2001, at
57.




The MOU has two parts, one dealing with use of WARF's patent
rights, and one dealing with use of WARF's approved ES cell lines.
The first part of the MOU provides that WiCell allow PHS to use its
patent rights in research involving WARF's approved ES cell lines
and third-party-approved cell linesm and grants third parties supplying
approved ES cell lines to PHS researchers "a limited, revocable, non-
commercial, research license" to WARF's patent rights5 9 The first
part of the MOU also gives WiCell reach through intellectual prop-
erty rights in any commercial products that stem from PHS's re-
search 0
The second part of the MOU allows PHS researchers to use
WARF's five approved ES cell lines subject to the following condi-
tions: ownership of the ES cell lines shall remain with WiCell;9' the
ES cell lines are not to be used for diagnostic or therapeutic pur-
poses;92 the ES cell lines must be used in compliance with applicable
statutes, regulations, and guidelines;93 and the ES cell lines are only to
be used for teaching or noncommercial research purposes.94 The
second part of the MOU also grants WiCell reach through intellectual
property rights to commercial products that are created with their
approved ES cell lines.9" WARF will extend the same terms from the
88. Memorandum of Understanding Between WiCell Research Institute, Inc. and Public
Health Service, U.S. Department of Health and Human Services § l(a-b) (Sept. 5, 2001),
available at http://www.nih.gov/news/stemcellfWicellMOU.pdf.
89. The license only applies when the third-party-approved lines are used for teaching or
noncommercial research purposes. Commercial use of third party lines requires a separate
licensing agreement with WiCell or WARF. Id. at § 1(c).
90. Section 1(d) of the MOU provides:
The Parties recognize that Wisconsin Patent Rights may be used in PHS research to
make patentable discoveries ("PHS Patent Rights"), which themselves may eventually
be the basis of commercial products that benefit public health. Any grant of Wisconsin
Patent Rights that may be needed by a third party for commercialization of PHS Pat-
ent Rights shall be done by a separate written agreement with WiCell permitting such
use of Wisconsin Patent Rights under terms not less favorable than other similar com-
mercial licenses to the extent such rights are available.
Id. at § l(d).
91. Id. at § 2(a).
92. Id. at § 2(b).
93. Id. at § 2(c).
94. Commercial use of the ES cell lines requires a separate agreement with WiCell. Id. at §
2(d).
95. Section 2(h) of the MOU provides:
The Parties recognize that Wisconsin Materials may be used in the PHS research pro-
gram to make discoveries of different materials ("PHS Materials") which themselves
may eventually be the basis of commercial products that benefit public health. Any
grant of rights to Wisconsin Materials or Wisconsin Patent Rights that may be needed
by a third party for commercialization of PHS Materials shall be done by a separate
written agreement with WiCell permitting such use of Wisconsin Materials or Wiscon-
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MOU, which governs only technology transfer to PHS (NIH) re-
searchers, to researchers at nonprofit institutions that receive grants
from NIH, provided those researchers enter a separate written
agreement with WiCell.
96
WARF's '806 patent potentially makes it the gatekeeper through
which all use of ES cells approved for federal research funding under
President Bush's plan must pass.9 7 And this gatekeeper is not a
disinterested party; WARF's five approved human ES cell lines are
direct competitors of the other approved lines. WARF has said that
it intends to make all ES cell lines covered by its '806 patent widely
available to publicly funded researchers, but this gatekeeper role
seems like a dangerous amount of power to be held by a single entity
with a financial interest in five of the approved lines.98
When ES cell science reaches the point where commercial medi-
cal products are ready to be developed and made publicly available,
intellectual property rights will pose a formidable obstacle, spawning
litigation that could delay medical applications of ES cell science.
Illustrative of this is a suit recently filed in the United States District
Court for the Western District of Wisconsin by WARF against
Geron, a Menlo Park, California, biotechnology company that was
WARF's partner in the research that led to the '806 patent 9 In this
suit, WARF and Geron are wrestling for control over commercial
rights to develop products from cell types that can be made from
human ES cells.1° Geron holds exclusive commercial rights to
WARF's patent rights and approved ES cell lines to develop products
from six cell types, including nerves, liver, and heart muscle.1, Geron
also has an option to add exclusive commercial rights to twelve more
cell types that it wishes to exercise. 12 WARF has sued Geron to
block Geron's exercise of that option.10 3 Every cell type to which
Geron holds an exclusive commercial right is, of course, a type that
sin Patent Rights under terms not less favorable than other similar commercial licenses
to the extent such rights are available.
Id. at § 2(h).
96. Id. at § 4; NIH, supra note 81.
97. See Lemonick, supra note 86.
98. See id.; Friend, supra note 79.
99. Antonio Regalado & David P. Hamilton, Geron is Sued over Control of Stem Cells,







WARF is not free to commercially license to other entities. This is
very high stakes litigation. Somewhere down the road, the scope of
WARF's '806 patent will probably also need to be litigated. All of
this litigation slows down ES cell research and wastes resources that
could be devoted to furthering that research.
2. Methods of Avoiding the Obstacles Created by Property Rights
Companies have begun developing ways to work around
WARF's '806 patent. For example, BresaGen has reported that it has
applied for a patent on a new method of isolating ES cells that would
not infringe WARF's '806 patent.104 BresaGen has not yet used the
method to isolate human ES cells, but it hopes to do so soon.15 But,
of course, human ES cell lines developed with these new techniques
will not be eligible for federal research funding under President
Bush's plan.
This is a major reason why the government policy of funding ES
cell research needs to be broadened. A broader funding approach
would give government-funded researchers the flexibility to work
around existing property rights in human ES cell lines. Researchers
would be free to develop new methods of deriving ES cell lines that
would allow them to circumvent existing intellectual property rights.
This would result in cheaper research and, eventually, less expensive
medical applications. It would also eliminate the possibility that a
single patent holder could hold up all government-funded ES cell
research.
B. Flight of Scientists
Another consequence of the funding limitations imposed by the
Bush plan for human ES cell research funding is the effect that it has
on where scientists choose to live and work. Simply put, scientists will
choose to locate themselves in places that are conducive to their
work. Obviously, the availability of government research funding is a
factor in determining a location's conduciveness. There are also
other less obvious burdens that accompany the denial of federal
research funding for human ES cell research. For instance, the NIH
is very careful to make sure that there is no intermingling between
federally funded research and ES cell research that is barred from
104. Friend, supra note 79.
105. Id.
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federal funding. 1°6 This has forced many scientists to segregate their
human ES cell work completely from their other work, often being
forced to move it off campus, even in cases where the scientist offers
to reimburse the NIH for any overhead costs human ES cell projects
share with other work.
10 7
Due to frustration from restrictive funding of ES cell research,
Roger Pedersen, formerly of the University of California, San Fran-
cisco, announced in July 2001 that he was leaving the United States
and emigrating to Great Britain where he felt he would enjoy "the
possibility of carrying out [his] research with human embryonic stem
cells with public support."' 18 Dr. Pedersen made his announcement
on the heels of President Bush's announcement of his new human ES
cell research funding policy and Great Britain's Medical Research
Council's announcement that it would create a stem cell bank that
uses spare embryos donated by thousands of couples undergoing IVF
treatment. 109 In an article explaining his emigration, Dr. Pedersen
wrote that the Bush plan for federal funding only on existing human
ES cell lines "confer[s] an advantage on countries such as Britain and
Canada, where there is government support for a wider range of stem
cell research activities." 110 Dr. Pedersen also warned: "The potential
benefits of stem cell research promise to transform healthcare and
stimulate economic growth. But they will accrue to countries where
the policies and funding encourage, rather than hobble, the stem cell
enterprise."" 1
Indications are that Dr. Pedersen's departure may be the first
drop in a flood should the United States federal ES cell research
funding policy remain unchanged."2 It already appears that the
106. Aaron Zitner, Uncertainty Is Thwarting Stem Cell Researchers Policy: A Top Scientist is
Leaving for Britain, as Human Embryo Cell Funding in U.S. Remains Unsolved, L.A. TIMES,
July 16,2001, at Al.
107. Id.
108. Id.
109. David Firn, Professor Warns US Will Miss Out over Stem Cells, FIN. TIMES, Aug. 15,
2001, at 1, available at 2001 WL 25577487.
110. Roger Pedersen, A Better Culture for Stem Cell Research, FIN. TIMES, Aug. 15, 2001, at
15.
111. Id.
112. See Anthony Shadid, Stem Cell Researchers Mull Move Overseas, BOSTON GLOBE,
August 9, 2001, at Al. Similarly, the United States may see an emigration of private research
funds.
Jim Clark, founder of several Silicon Valley companies, has decided to withhold $60
million of the $150 million he had pledged to Stanford University for a center for
biomedical engineering and science because he has concluded that the politicization of
stem cell research in the United States means that the "new future for medicine and
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United States may not be at the front of ES cell science: only twenty-
seven of the seventy-eight cell lines approved for funding under the
Bush plan belong to organizations in the United States.113 ES cell
science in the United States will suffer further losses if federal fund-
ing of human ES cell research is not broadened.
C. Limited Diversity of ES Cell Lines as an Obstacle to Developing
Transplantation Products
Another shortcoming of the Bush plan is that by only allowing
funding of research on seventy-eight existing human ES cell lines, it
places obvious constraints on the diversity of the cell lines. Diversity
of human ES cell lines figures to be particularly valuable to the
development of transplantable products from the ES cell lines, a
major end goal of ES cell science." 4
As with any transplantation technology, a major concern of using
human ES cell-derived transplantation products is the potential for
immune rejection."5 Human cells express cell-surface proteins known
as human-leukocyte-associated ("HLA") antigens." 6 The genes that
code for these HLA antigens are highly polymorphic; that is, it is very
rare for two individuals, save two identical twins, to have an identical
set of HLA antigens. 7 The human immune system uses these HLA
antigens to identify cells as either belonging to the body or as for-
eign.1 8 Cells identified as foreign, the ones with HLA antigens
different from those of the body's cells, are attacked by the immune
system."' This immune response poses a serious obstacle to trans-
plant procedures. 120 A key to success in creating transplantable
products from human ES cell lines will be matching HLA antigens of
the transplant recipient as closely as possible.'2' Success in matching
biology and for resulting entrepreneurship" that he had intended to stimulate at Stan-
ford will instead occur abroad, especially in the U.K.
Capron, supra note 39, at 697
113. NIH Human Embryonic Stem Cell Registry, http://escr.nih.gov/.
114. See Ceci Connolly et al., Viability of Stem Cell Plan Doubted, WASH. POST, August 20,
2001, at Al.
115. DEP'T OF HEALTH AND HUMAN SVCS., supra note 6, at 17.
116. ALBERTS, supra note 10, at 1229-30.
117. Id. at 1230.
118. See id. at 1229-30.
119. Id. at 1230.
120. Id. at 1229-30
121. See Connolly et al., supra note 114. Another potential way around the problem of
HLA antigens and rejection is the use of somatic cell nuclear transfer technology ("therapeutic
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HLA antigens as closely as possible to transplant recipients will be
directly proportional to the genetic diversity of available human ES
cell lines.
Additionally, it appears that the vast majority of the seventy-
eight human ES cell lines meeting President Bush's criteria for
federal funding were derived from embryos from Caucasian couples,
and a few were derived from embryos of Asian couples.12  While the
correlation between racial diversity and genetic diversity is debatable,
this homogenous selection should at least raise some eyebrows.
12 3
Perhaps the most odious concern created by this lack of racial diver-
sity is the possibility of the discriminatory availability of ES cell
treatments. While current HHS Secretary Tommy Thompson has
assured the public that the private sector will fill any voids in the
current diversity of available ES cell lines, it seems unlikely that
private companies would be clamoring to develop ES cell products
tailored to minority populations because of a lack of financial incen-
tives. 124
In order to meet the major end goal of creating transplantation
products using ES cell technology, ES cell scientists need as large a
pool of ES cell lines as is possible. The Bush plan limits that pool to
seventy-eight ES cell lines. A broader plan to federally fund human
ES cell research, however, would significantly increase that pool,
thereby increasing scientists' chance of meeting their end goals.
D. Xenotransplantation Concerns
Researchers face another substantial obstacle to meeting their
end goal of developing transplantation products from ES cell tech-
nology: the Food and Drug Administration's ("FDA's") xenotrans-
plantation guidelines. It appears that transplantation products
derived from the seventy-eight Bush-approved ES cell lines would be
barred from use in humans by these guidelines. 25 A broader plan of
cloning"). DEP'T OF HEALTH AND HUMAN SERVS., supra note 6. The very controversial topic
of therapeutic cloning is beyond the scope of this Note.
122. Jon Entine & Sally Satel, Inserting Race into the Stem Cell Debate, WASH. POST, Sept.
9, 2001, at BI.
123. See id.
124. Id.; see Connolly et al., supra note 114.
125. See FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: SOURCE ANIMAL, PRODUCT,
PRECLINICAL, AND CLINICAL ISSUES CONCERNING THE USE OF XENOTRANSPLANTATION
PRODUCTS IN HUMANS 6 (2001), available at http://www.fda.gov/cber/gdlns/clinxeno0201.pdf;




federally funding human ES cell research would allow researchers to
develop transplantation products from new ES cell lines that would
meet FDA xenotransplantation guidelines.
Xenotransplantation is defined by the FDA as "any procedure
that involves the transplantation, implantation, or infusion into a
human recipient of either (a) live cells, tissues, or organs from a
nonhuman animal source, or (b) human body fluids, cells, tissues or
organs that have had ex vivo contact with live nonhuman animal cells,
tissues or organs.' 126 Concerns over the possibility of the introduction
and spread of infectious agents of animal origin into the human
population have led to the FDA's creation of guidelines for the use of
xenotransplantation products in humans. 27 These guidelines place
very stringent limits on using any xenotransplantation products in
humans. While these guidelines have been released in draft form
only, the FDA is currently following them.
128
It is believed that all existing human ES cell lines that meet
President Bush's criteria for federal research funding are "xenotrans-
plantation products" under FDA guidelines, and would therefore be
subject to the guidelines' stringent restrictions. 29 This is because
these ES cell lines were all grown using mouse feeder cells and bovine
serum. 30 A technique for maintaining ES cell lines without using
mouse feeder cells or bovine serum has recently been developed, 3'
but any new ES cell lines developed and maintained with this tech-
nique would not be eligible for federal funding under President
Bush's plan.
The magnitude of the obstacle that the FDA xenotransplantation
guidelines place in front of human ES cell research funded under
President Bush's plan is unclear. Harvard Medical School surgeon
Hugh Auchincloss, Jr., chairman of an FDA committee that reviewed
the xenotransplantation issue, has stated that the FDA xenotrans-
126. FOOD & DRUG ADMIN., supra note 125, at 6.
127. Id. at 2; see DEP'T OF HEALTH AND HUMAN SERVS., supra note 6, at 95. An example
of the introduction of an infectious agent of animal origin into the human population is the
infamous bovine spongiform encephalopathy, better known as mad cow disease, and its human
equivalent Creutzfeldt-Jakob disease. Id.
128. Gillis & Connolly, supra note 125.
129. See id.; see also FOOD & DRUG ADMIN., supra note 125, at 6.
130. DEP'T OF HEALTH AND HUMAN SERVS., supra note 6, at 95-96; Jill Carroll & Jim
VandeHei, Mouse Cells in Stem Lines May Limit Use, WALL ST. J., Aug. 24, 2001, at A3.
131. See Chunhui Xu et al., Feeder-Free Growth of Undifferentiated Human Embryonic Stem
Cells, 19 NATURE BIOTECHNOLOGY 971 (2001).
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plantation policy is stringent but is not an absolute bar to research. 13 2
Jay Leftkowitz, a senior White House adviser who helped draft
President Bush's stem cell policy, commented that the FDA policy
will not be a barrier at this early stage of human ES cell research.
33
He says that years of basic research must be conducted before trans-
plantation and the FDA regulations are even a relevant consideration
and that, by that time, scientists will have found a way to comply with
FDA guidelines.134 It is worth noting however, that Mr. Leftkowitz's
comments seem to imply that, at some time in the future, federal ES
cell research funding policy would need to be changed to provide
funding for research on cell lines propagated with FDA-compliant
techniques.
In sum, while FDA xenotransplantation guidelines are of debat-
able importance at this early stage of human ES cell science, should
researchers accomplish their goal of transforming human ES cells into
transplantable products, these guidelines will be of paramount
concern. While a broader approach to federal funding of human ES
cell research would allow scientists to develop ES cell lines that are
compliant with FDA guidelines, President Bush's stem cell policy
does not allow this option. Scientists working under President Bush's
plan would instead be forced to try to find ways to comply with FDA
guidelines while using ES cell lines that had been exposed to mouse
feeder cells and bovine serum, an endeavor that seems tenuous at
best.
CONCLUSION
United States policy for federally funding human ES cell re-
search needs to be broadened. By limiting federal funding to re-
search on just seventy-eight ES cell lines, President Bush's plan will
prevent ES cell researchers from reaching their end goal of using ES
cell technology to create revolutionary medical treatments. If the
taxpayers are going to fund ES cell research, they deserve the re-
search to be funded in a way that will allow it to produce the benefits
that they desire.
132. Gillis & Connolly, supra note 125.
133. Id.
134. Id.
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